Sat.May 03, 2025 - Fri.May 09, 2025

article thumbnail

Health equity can be a competitive advantage: What pharma leaders need to know

pharmaphorum

As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have a chance to lead aligning innovation with access drivers and gaining a competitive edge in a changing global landscape.

article thumbnail

Bill Gates to accelerate spending at his foundation — then wind it down

STAT

Philanthropist Bill Gates announced Thursday that he will wind down his massive charity in 20 years, doubling spending over that time to accelerate the work it hopes to achieve. Gates made the announcement on the 25th anniversary of the launch of the Gates Foundation, the third-largest player in international philanthropy. He said the foundation would spend $200 billion between now and 2045, when its operations will wind down.

317
317
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant

Pharmafile

Sanofi and Clayton, Dubilier & Rice (CD&R) have officially closed the sale of a controlling 50% stake in Opella, Sanofis consumer healthcare division, positioning Opella as a new independent leader in the global consumer health space. The deal brings Sanofi approximately 10bn in net cash proceeds. Sanofi retains a 48.2% share in Opella, with Bpifrance […] The post Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant appeared first on Pharmafile.

100
100
article thumbnail

With TV ads under threat, here’s how pharma can leverage social media

PharmaVoice

RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.

182
182
article thumbnail

Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

article thumbnail

Prasad’s FDA appointment pressures cell and gene therapy stocks

BioPharma Dive

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.

83
article thumbnail

Opinion: An evidence-based way to make Medicaid less bureaucratic and more efficient

STAT

As a primary care physician serving Medicaid patients, I recently witnessed a preventable hospitalization that perfectly illustrates America’s health care dysfunction. My homebound patient with heart failure needed a routine lab test to adjust their medication. While commercially insured patients can access electronic lab orders, my patient’s Medicaid plan contracted exclusively with a laboratory requiring physical forms by mail.

Hospitals 253

More Trending

article thumbnail

With compounders out of the way, Lilly and Novo go after each other

PharmaVoice

The two obesity leaders are pulling on all levers to stay on top of the market.

article thumbnail

Patent box tax incentives pharmaceutical innovation

Drug Patent Watch

"The Patent Box Tax Incentive: A Game-Changer for Pharmaceutical Innovation? As the pharmaceutical industry continues to drive groundbreaking research and development, a lesser-known tax incentive has emerged as a key catalyst for innovation. The Patent Box tax regime, introduced in the UK in 2013, has been hailed as a success in fostering a culture of R&D and entrepreneurship.

82
article thumbnail

STAT+: Compounders lose legal battle with FDA over removal of Eli Lilly’s weight loss drug from a shortage list

STAT

A federal judge has sided with the U.S. Food and Drug Administration over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine and the Mounjaro diabetes treatment — from a shortages list kept by the agency. The move means that patients will no longer have access to cheaper versions from compounding pharmacies.

article thumbnail

RFK Jr launches database project to explore autism causes

pharmaphorum

A project to use federal databases to identify the "root causes of autism" has been launched by HHS, but there are concerns about its credibility

76
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst

PharmaVoice

Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

147
147
article thumbnail

How counterfeiters are breaching India’s QR code system

Express Pharma

There is growing concern that a sizable proportion of medicines in India could be unsafe for patients. For example, on April 19, 2025, CDSCO published three lists of Not of Standard Quality (NSQ) drug alerts for March 2025, spanning 131 product batches. The most common reason cited is failing the dissolution test as per IP 2022. In the recent past, pharma associations as well as many individual pharma companies have clarified the differences between various terms: spurious, NSQ and counterfeits,

article thumbnail

Recursion cuts nearly half of its pipeline

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, there’s been a lot of discussion lately about how the U.S. can stay competitive in science, biomedical innovation, and drug development. We’ve got several pieces of news relevant to that issue today.

article thumbnail

AI specialist Recursion trims pipeline in latest shakeup

BioPharma Dive

The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote in a note to investors.

118
118
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications

PharmaVoice

With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.

130
130
article thumbnail

Biocon Biologics gains market access coverage for Yesintek in the US

Express Pharma

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab). The market access agreements from numerous plans represent over 100+ million lives in the United States. Express Scripts has added Yesintek to the National Preferred Formulary (NPF) effective March 21, 2025.

article thumbnail

Opinion: How to stop the shift of drug discovery from the U.S. to China

STAT

Five years ago, U.S. pharmaceutical companies didn’t license any new drugs from China. By 2024, one-third of their new compounds were coming from Chinese biotechnology firms. Why are U.S. drugmakers sending their business to China? As in many other industries, it’s so much cheaper to synthesize new compounds inside Chinese biotechnology firms once a novel biological target has been discovered in American laboratories.

article thumbnail

Viatris’ new form of old pain drug scores in large trials

BioPharma Dive

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical acute pain. Viatris now plans to file for approval this year.

73
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand

Pharmaceutical Technology

Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and diabetes drugs.

article thumbnail

Three CAR-T therapies forecasted to capture over 70 per cent of T-Cell immunotherapy market in 2025

Express Pharma

T-cell immunotherapies (TCI) are redefining cancer care, with chimeric antigen receptor T-cell (CAR-T) therapies witnessing significant momentum. In 2025, just three drugs- Carvykti by Legend Biotech, Yescarta by Gilead Sciences, and Breyanzi by Bristol-Myers Squibb (BMS) are expected to capture over 70 per cent of the global T-cell immunotherapy market, according to GlobalData.

64
article thumbnail

STAT+: Vinay Prasad tapped to run FDA center that regulates vaccines, gene therapies

STAT

WASHINGTON — Vinay Prasad, an academic and fierce critic of the medical mainstream, will be the next director of the Food and Drug Administration center that oversees the regulation of vaccines, gene therapies, and the blood supply.  Prasad, previously an epidemiology professor at the University of California, San Francisco, has sharply criticized the FDA in the past, including the Center for Biologics Evaluation and Research, the unit he will now lead.

Vaccines 364
article thumbnail

New CBER Director Appointed

PharmaTech

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.

59
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Eli Lilly signs $415m deal for Alchemab’s ALS therapy  

Pharmaceutical Technology

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

91
article thumbnail

Roquette restructures company, appoints new leaders following the acquisition of IFF Pharma Solutions

Express Pharma

Roquette, a provider of plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces a new organisation following its acquisition of IFF Pharma Solutions, announced on May 1. The new organisation aims to enhance agility and customer responsiveness. Now with over 11,000 employees, 40 manufacturing sites and a network of global R&D and Innovation Centres, the company aims to expand its global footprint and the diversity of its portfolio.

article thumbnail

STAT+: As financial prospects for gene therapies dim, an ambitious charity picks up the torch  

STAT

MILAN — For more than three decades, a charity here has funded research aimed at developing medicines for genetic diseases. Recently, though, it added an unusual new role — as a gene therapy company of sorts.  The charity, the Telethon Foundation, took ownership from a small biotech of a drug that has been approved in Europe to treat an ultra-rare immune disorder called ADA-SCID.

Immunity 338
article thumbnail

UK trumpets a trade deal with India - but pharma isn't happy

pharmaphorum

Various industries have welcomed news of a trade deal between the UK and India, but Britain's pharma sector isn't among them

101
101
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Majority of Europeans trust technology to improve healthcare, Johnson & Johnson survey finds

Pharmafile

A global survey by Johnson & Johnson MedTech has revealed that a majority of Europeans are willing to share their health data in exchange for more personalised care signalling growing public trust in the role of technology in healthcare. Conducted between August and September 2024, the survey gathered responses from both the general public […] The post Majority of Europeans trust technology to improve healthcare, Johnson & Johnson survey finds appeared first on Pharmafile.

66
article thumbnail

FABA, IIL, and ABF launch finishing school programme in Hyderabad

Express Pharma

The Federation of Asian Biotech Associations (FABA), Indian Immunologicals (IIL), and Agri Biotech Foundation (ABF) jointly inaugurated a finishing school programme at the Agri Biotech Foundation campus, Rajendra Nagar, Hyderabad. This programme gap between academic learning and industry readiness in biotechnology, The programme, which will run until June 4, 2025, provides intensive, hands-on training in wet lab facilities, offering real-world experience in microbiology, molecular biology, and c

article thumbnail

STAT+: Flatiron Health veterans raise $25 million for AI tool to forecast drug toxicity

STAT

In January, San Francisco’s Union Square was bustling with hordes of drug developers and investors, pounding the pavement on their way from meeting to meeting. But Rohan Ganesh, an investor at the VC firm Obvious Ventures, wasn’t among them. He only agreed to hear one company’s pitch during this year’s J.P. Morgan Healthcare Conference.

article thumbnail

GP premises investment must improve pharmacist workspaces, urges PDA

The Pharmacist

New government investment for general practice premises must ensure that pharmacists working in these settings have the facilities they need to do their job properly, the Pharmacists' Defence Association (PDA) has urged. It comes as more than 1,000 GP practices in England will be given funding from the government for quick fix estate upgrades this […] The post GP premises investment must improve pharmacist workspaces, urges PDA appeared first on The Pharmacist.

59
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.